key: cord-0789059-zcwwm0il
authors: Yusuff, Hakeem; Zochios, Vasileios; Brodie, Daniel
title: Thrombosis and coagulopathy in COVID-19 patients receiving ECMO: a narrative review of current literature
date: 2022-03-31
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2022.03.032
sha: 96c55a8790c5a1b3e1b576a58f6a993522e623b7
doc_id: 789059
cord_uid: zcwwm0il

Extracorporeal membrane oxygenation (ECMO) is an established part of the treatment algorithm for coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS). An intense inflammatory response may cause an imbalance in the coagulation cascade making both thrombosis and bleeding common and notable features of the clinical management of these patients. Large observational and retrospective studies provide a better understanding of the pathophysiology and management of bleeding and thrombosis in COVID-19 patients requiring ECMO. Clinically significant bleeding, including intracerebral hemorrhage is an independent predictor of mortality, and thrombosis (particularly pulmonary embolism) is associated with mortality, especially if occurring with right ventricular dysfunction. The incidence of heparin-induced thrombocytopenia is higher than the general patient cohort with acute respiratory distress syndrome or other indications for ECMO. The use of laboratory parameters to predict bleeding or thrombosis has a limited role. In this review, we discuss the complex pathophysiology of bleeding and thrombosis observed in patients with COVID-19 during ECMO support, and their effects on outcomes.

The inflammatory state associated with COVID-19 may amplify the pro-inflammatory effect of ECMO. [1] [2] [3] The clinical consequences of this are bleeding, along with other disorders of coagulation, including thrombosis. Coagulation function and assessment is additionally complicated by patients receiving anticoagulation to ensure circuit patency. ECMO has become an established part of the treatment algorithm for the acute respiratory distress syndrome (ARDS), 4,5 including patients with COVID- 19 . In contrast to COVID-19 patients not receiving ECMO, bleeding is more prevalent in ECMO patients. 2, 6 Recent studies investigating the role of therapeutic anticoagulation in patients not receiving ECMO with severe COVID-19 pneumonitis have demonstrated an increase in bleeding complications. 7 In this review we aim to present and discuss the most recent studies on this subject and assess the impact of bleeding and thrombosis on outcomes, including mortality.

We searched MEDLINE and EMBASE from commencement date through to the beginning of January 2022, for the following search terms (in the title or abstract): 'ECMO'; 'extracorporeal membrane oxygenation'; 'COVID-19'; 'coronovirus disease 2019'; 'COVID-19 coagulopathy'; 'thrombosis'; 'hemorrhage'; and 'coagulopathy', in isolation and in combination without restrictions. A mixture of free text and subject headings mapped to the thesaurus to ensure a thorough search of the selected databases were used. In addition, we searched for bibliographic references of relevant articles in order to identify relevant studies to be included in this narrative review.

COVID-19 is a multi-system disorder with a prominent respiratory component. The commonest route of infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is via the respiratory tract with entry into pneumocytes via the ACE 2 receptors. 8 ACE 2 receptors are also found in the gastrointestinal system, heart, and kidney; hence the pathological effects of infection are common in these sites as well. 3 Endocytosis of the virus receptor complex results in widespread endotheliopathy and pulmonary vascular microthrombosis. 2, 6, 9 Clinically, in combination with COVID-19-related pneumonia, this may result in hypoxemia potentially requiring supplemental oxygen, non-invasive forms of mechanical ventilation, invasive mechanical ventilation or ECMO support.

Extracorporeal membrane oxygenation support is associated with a biomaterial-induced inflammatory response associated with the activation of coagulative and inflammatory cascades. 10 The levels of pro-inflammatory cytokines rise rapidly with resultant leukocyte activation which in severe forms may result in endothelial injury and micro-circulation disruption. 10 The overarching coagulation state in patients receiving ECMO support is initially prothrombotic and this state tends to predominate for the time spent on ECMO support, hence the need for continuous anticoagulation in most cases. There have been reports where the entire ECMO journey has been carried out without the need for anti-coagulation. 11, 12 Anticoagulant processes such as the effect of acquired von Willebrand disease, loss of platelet glycoprotein IIc and IIIb receptors, fibrinolysis and oxygenator sequestration of micro-thrombi may contribute to bleeding. In most instances, the predominant state remains prothrombotic. 13 A contrasting clinical picture, where bleeding tendency features as the predominant coagulation state may be encountered in intense inflammatory states (e.g. COVID-19 or severe bacterial sepsis). As a result, an increased incidence of clinically significant bleeding occurring in these states. 9, 14 Hemorrhage

The earliest reports from Wuhan, China, on patients with COVID-19 pneumonitis managed with ECMO suggested a bleeding rate of 14% (3 out of 21 patients) without demonstrable coagulopathy in the study cohort. 15 In particular, only one patient (4.7%) developed intracranial hemorrhage. This is congruent with the report from the Extracorporeal Life Support Organization (ELSO) registry, where in the initial months of the pandemic, central nervous system (CNS) hemorrhage occurred in 6% of patients receiving ECMO for COVID- 19 . 16 A review of 83 patients with COVID-19 pneumonitis managed with ECMO from Paris spanning a similar period to May, 2020, demonstrated a 5% intracranial bleeding rate; however, the overall rate of massive hemorrhage was significantly higher (42%). 17 (Table   1 )The rate of intracranial bleeding was notably higher than the bleeding rate reported in the ECMO to Rescue Lung Injury in Severe ARDS (EOLIA) trial (2%). 17, 18 This has been attributed to higher dose anticoagulation regimens, SARS-CoV-2-associated vasculitis and micro-bleeds associated with critical illness.

An observational study from the UK looking at patients in the same period, where anticoagulation had been managed within a tight range (anti-Xa levels 0.3 -0.5), showed an overall numerically lower bleeding rate (30.9%). However, the rates of intracranial hemorrhage were considerably higher (10.5%), a finding associated with a 5.97-fold increase in mortality. 1 This suggests that the development of intracranial hemorrhage could be related in part to SARS-CoV-2-related vasculitis and inflammation rather than anti-coagulation; however, their effects may be synergistic. A study comparing the bleeding and thrombosis rates between patients with COVID-19 and influenza pneumonitis who had similar characteristics and required ECMO support showed similar rates of intra-cerebral hemorrhage (16% vs 14%). 19 It would be plausible to hypothesize that intracranial hemorrhage may be related, at least in part, to the degree of inflammation associated with the viral infection, which is phenotypically expressed most in the sickest COVID-19 patients, a cohort which may be overrepresented by those receiving ECMO. It is also plausible that the added inflammatory effect from being exposed to an extracorporeal circuit and the required anticoagulation would further amplify this effect. This hypothesis is supported by the lack of evidence of a reduction in bleeding rates when intravenous heparin anticoagulation is compared with alternative forms of systemic anticoagulation (e.g. argatroban) both in COVID-19 and non-COVID-19

cohorts managed with ECMO. 20, 21 The impact of intracranial bleeding on mortality was also demonstrated in a recent analysis of the ELSO registry including all patients receiving ECMO for respiratory failure prior to the COVID 19 pandemic. Most of the patients had nonviral pneumonia (26.9%) with viral pneumonia constituting 20.6% of patients. Bleeding was strongly associated with in-hospital mortality with intra-cranial bleeding having the highest association with mortality. (OR 5.71 (4.02 -8.09). 22 A recent review of the ELSO registry sought to identify the risk factors for bleeding in patients receiving VV ECMO for respiratory failure from all causes. 23 Factors such as pre-ECMO cardiac arrest, surgical cannulation, a greater degree of pre-cannulation hypoxemia, severe metabolic and lactic acidosis, high respiratory rate with mechanical ventilation, pre-ECMO surgery and shock were predictive of bleeding. These parameters were included in a prediction model to aid the identification of patients at risk of bleeding. In the context of COVID-19, the limitation of this model is that data on anticoagulation, laboratory results and transfusion were not included, and the model could not account for the weighting of the cause of respiratory failure on the various clinical variables described in predicting bleeding. The model does suggest that the patients with risk factors that would be expected to increase bleeding risk are, in fact, more likely to bleed. 23

The prevalence of thrombosis in COVID-19 has been extensively described in the literature.

The incidence of thrombosis has been reported to be between 20% and 30% in hospitalized patients 6,24,25 most of which is diagnosed as pulmonary embolism. In the context of ECMO support, pulmonary embolism could contribute to the physiological deterioration of the patient necessitating ongoing need for ECMO support or it may complicate the ECMO run.

During the first wave of the pandemic, an analysis of COVID-19 patients managed with ECMO in the UK showed a thrombosis incidence of 63% with majority of the patients presenting with isolated pulmonary embolism (29.6%). 1 The development of pulmonary embolism was independently associated with mortality. 1 In a French retrospective review undertaken also during the initial wave of COVID-19, the most prevalent thrombotic complication was found to be pulmonary embolism (19%). 26 A similar trend has been demonstrated in other studies with the incidence being as high as 69.8% in one report. [27] [28] [29] [30] ( Table 1 ). It is difficult to ascertain whether the pulmonary embolism in these studies developed before or after ECMO support was initiated. The comparative rate of pulmonary embolism in non-COVID 19 patients receiving ECMO is also difficult to ascertain. Data on the incidence and impact of pulmonary embolism was not collected in the EOLIA study. 18 These findings align with recent reports describing the impact of right ventricular (RV) failure on COVID-19 outcomes. 31,32 It is very likely that in addition to hypoxemia and hypercarbia, the added burden of pulmonary embolism in selected patients increases the afterload on the RV despite optimal respiratory (veno-venous) ECMO support and ultra-lung protective ventilatory settings.

The ELSO registry in the first wave of the pandemic showed the rate of oxygenator failure was 9%. 16 Oxygenator failure is most often attributed to the development of thrombi and hence this was likely driven by a thrombogenic process occurring in the ECMO circuit despite full anticoagulation. 33 The above referenced reviews of patients in the UK and France found an incidence of ECMO circuit related thrombosis of 9.9% 1 and 4% 26 respectively. The occurrence of ECMO circuit thrombosis was not found to be associated with increased mortality. 1 Compared with adult respiratory ECMO cases in the year prior to the pandemic, the rates of complications associated with ECMO circuit thrombosis were similar once normalized for time on ECMO (which is longer in the COVID-19 patients). 22 ,34 This is observational data which does not account for changes anticoagulation practices, which were known to have changed at many centers. Thrombosis rates per hour of ECMO are the same despite higher levels of anticoagulation in the COVID-19 cohort, suggesting a higher propensity for thrombosis. There is no evidence to definitively support this notion.

It has been reported recently that the incidence of heparin-induced thrombocytopenia (HIT) is higher in the context of COVID-19 disease managed with ECMO than in patients supported with ECMO for other indications. The reported incidence of HIT during ECMO in patients with COVID-19 is 10.52% (compared to 0.36% -7.8% [35] [36] [37] [38] in the general non-COVID-19 ECMO cohorts) with 62.5% presenting with thrombosis. 1 This may be an underestimate given the difficulties of diagnosing HIT in this context, with several other plausible causes of thrombocytopenia possible. 39 A higher incidence of HIT likely to be contributory to the increased incidence of thrombosis.

ECMO circuit thrombosis or failure creates challenges, especially if it is associated with significant bleeding. The interventions required to control bleeding such as transfusion of blood products and use fibrinolytics are likely to increase the clot burden in the ECMO circuit. Clots in the circuit would worsen the coagulopathy, cause haemolysis 40 and gas exchange in the membrane oxygenator would be impaired. This creates a vicious circle which may necessitate the need to change the ECMO circuit. This is a complex and critical intervention which should be carried out by an experienced team after weighing the risks and benefits. 40

Many of the hallmark laboratory features of COVID-19 are reflective of a hyperinflammatory state. 41 There is raised ferritin, C-reactive protein, white blood cell count, lymphopenia, raised fibrinogen and elevated D-dimer. 41 A clinical phenotype characterized by increased bleeding tendency has been described and named COVID-19-associated coagulopathy. This is characterized by a 3-4-fold rise in Ddimer, a modest rise in prothrombin time and thrombocytopenia (< 150 x 10 9 /L). These parameters have been associated with increased need for critical care and increased mortality rates among patients with COVID-19. 42, 43 Patients with severe COVID-19 presenting with low fibrinogen or overt disseminated intravascular coagulation have been found to have poor outcomes. C-reactive protein, white cell count, platelet count, prothrombin time, fibrinogen and D-dimer are often recommended for inclusion as a key part of the laboratory profile required to assess COVID-19 patients. 43 In one study, there was a strong association between thrombosis and a raised lactase dehydrogenase level. 1 This is likely to be reflective of acute tissue damage and diffuse alveolar damage associated with COVID-19.

In the context of ECMO support with concurrent use of intravenous unfractionated heparin, ECMO associated thrombin generation, cyto-trauma, and inflammation, it becomes more difficult to correctly ascribe any coagulation derangement seen to one specific etiology. 1, 14, 18, 44 Patients presenting with laboratory features of COVID-19-associated coagulopathy either before or early during ECMO support would be expected to be more prone to developing clinically significant bleeding complications. Recent studies have yet to demonstrate this and associations with mortality have not been conclusively shown. 1, 26 The influence of COVID-19-associated coagulopathy is likely to act synergistically with the hyperinflammatory state associated with COVID-19 and ECMO to produce clinically significant bleeding and thrombosis. Echocardiography in this context would be useful to guide management. 45 Where right ventricular support is required, consideration should be given to ECMO configurations that would provide mechanical right ventricular support e.g., veno-venous arterial (VVA) ECMO or veno-pulmonary arterial (V-PA) ECMO. 46, 47 Patients identified with COVID-19-associated coagulopathy should be regularly assessed for bleeding and this should be considered when planning for any surgical procedurese.g., percutaneous tracheostomy, thoracotomy, or chest drain insertion.

Patients with active bleeding should receive appropriate blood product replacement aiming for a platelet count > 50 X 10 9 / L, fibrinogen levels > 1.5g/L and prothrombin time <16.3 seconds. 42 The multi-disciplinary management of the severely bleeding COVID-19 ECMO patient should include expert hematology input, where needed. In addition, close monitoring of the function and patency of the ECMO circuit should be carried out at regular intervals. This should include monitoring of oxygenator transmembrane pressure, oxygen transfer across the oxygenator membrane, as well as serum LDH and plasma free hemoglobin. 40 This would facilitate the consideration of circuit-related coagulopathy occurring synergistically with COVID-19-associated coagulopathy for which an exchange of the ECMO circuit may be indicated. (Figure 2 )

The impact of bleeding and thrombosis on COVID-19 patients receiving ECMO is considerable and continues to be a major clinical feature of managing these patients, especially in those who do not survive. Expert manipulation and management of coagulation is required to reduce the impact on patient-centered outcomes. Future research should be directed at identifying the predictors of bleeding and thrombosis, as well as markers of prognosis in these patients, along with the selection of agents to improve coagulation management in this context.

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

medical advisory boards for Abiomed, Xenios, Medtronic, Inspira and Cellenkos. He is the President-elect of the Extracorporeal Life Support Organization (ELSO) and the Chair of the Executive Committee of the International ECMO Network (ECMONet). Hakeem Yusuff and Vasileios Zochios report no conflicts of interest. 

Impact of major bleeding and thrombosis on 180-day survival in patients with severe COVID-19 supported with veno-venous extracorporeal membrane oxygenation in the United Kingdom: a multicentre observational study

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus

Thrombosis and Coagulopathy in COVID-19 Patients Requiring Extracorporeal Membrane Oxygenation

The inflammatory response to extracorporeal membrane oxygenation (ECMO): A review of the pathophysiology

Heparin-free extracorporeal membrane oxygenation in a patient with severe pulmonary contusions and bronchial disruption

Heparin-free veno-venous extracorporeal membrane oxygenation in a multiple trauma patient: A case report

Current Understanding of How Extracorporeal Membrane Oxygenators Activate Haemostasis and Other Blood Components

Systemic inflammatory response syndrome is a major contributor to COVID-19-associated coagulopathy: Insights from a prospective, single-center cohort study

Extracorporeal Membrane Oxygenation for Coronavirus Disease 2019-Induced Acute Respiratory Distress Syndrome: A Multicenter Descriptive Study *

Extracorporeal membrane oxygenation for COVID-19: evolving outcomes from the international Extracorporeal Life Support Organization Registry

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome

A Comparison of Thrombosis and Hemorrhage Rates in Patients with Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation

Argatroban versus heparin in patients without heparin-induced thrombocytopenia during venovenous extracorporeal membrane oxygenation: a propensity-score matched study

Argatroban for Anticoagulation in Patients Requiring Venovenous Extracorporeal Membrane Oxygenation in Coronavirus Disease

Bleeding and thrombotic events in adults supported with venovenous extracorporeal membrane oxygenation: an ELSO registry analysis

HEROES V-V-HEmorRhagic cOmplications in Veno-Venous Extracorporeal life Support-Development and internal validation of multivariable prediction model in adult patients

Pulmonary Embolism in Patients with COVID-19: Awareness of an Increased Prevalence

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Six-Month Survival After Extracorporeal Membrane Oxygenation for Severe COVID-19

Six Month Mortality in Patients with COVID-19 and Non-COVID-19 Viral Pneumonitis Managed with Veno-Venous Extracorporeal Membrane Oxygenation

Extracorporeal membrane oxygenation in patients with severe respiratory failure from COVID-19

A Comparison of Thrombosis and Hemorrhage Rates in Patients with Severe Respiratory Failure Due to Coronavirus Disease 2019 and Influenza Requiring Extracorporeal Membrane Oxygenation

Impact of Right Ventricular Dysfunction on Mortality in Patients Hospitalized With COVID-19, According to Race

Different mechanisms of oxygenator failure and high plasma von Willebrand factor antigen influence success and survival of venovenous extracorporeal membrane oxygenation

Platelet Count Trends and Prevalence of Heparin-Induced Thrombocytopenia in a Cohort of Extracorporeal Membrane Oxygenator Patients

Prevalence and outcome of heparin-induced thrombocytopenia diagnosed under veno-arterial extracorporeal membrane oxygenation: a retrospective nationwide study

Clinically suspected heparin-induced thrombocytopenia during extracorporeal membrane oxygenation

Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis

How I approach membrane lung dysfunction in patients receiving ECMO

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Extracorporeal membrane oxygenation network organisation and clinical outcomes during the COVID-19 pandemic in Greater Paris, France: a multicentre cohort study

Right ventricular dysfunction in critically ill COVID

Extracorporeal Membrane Oxygenation for Patients With COVID-19 in Severe Respiratory Failure

Mechanical circulatory support devices for acute right ventricular failure